MEI Pharma, Inc., a late-stage pharmaceutical company headquartered in San Diego, CA, has been making steady strides in the development and commercialization of therapies aimed at treating cancer. The company's notable projects include Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is currently in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies. Alongside this, MEI Pharma has been developing Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. The company is also working on various other products such as ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer, and Pracinostat, an oral available histone deacetylase inhibitor. The latter is in Phase II clinical trial for treating patients with myelodysplastic syndrome. MEI Pharma has also entered into several critical agreements in the recent past, such as its license, development, and commercialization agreement with Kyowa Kirin Company, clinical collaboration with BeiGene, Ltd., license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA, and license agreement with Presage Biosciences, Inc. The company has come a long way since it was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.